Zim Laboratories Ltd. (ZIMLAB) AI Stock Analysis

• Market Cap: ₹6.10B
• Dividend Yield: N/A
• Average Volume (3M): 6.28K
• Price to Earnings (P/E): 96.1
• Beta (1Y): 1.17
• Revenue Growth: -1.22%
• EPS Growth: -52.32%
• Country: IN
• Employees: 556
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.35
• Shares Outstanding: 53,549,038
• 10 Day Avg. Volume: 5,950
• 30 Day Avg. Volume: 6,279
• PEG Ratio: -0.97
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 0.79
• P/FCF Ratio: -39.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: ₹120.00 ▲(68.75% Upside)
• Action: Reiterated
• Date: 05/21/26

Positive Factors

Balance Sheet Strength

Rising equity increases the company's capital base and financial resilience, providing a durable cushion against cyclical downturns and funding headroom for R&D, regulatory registrations, or capacity spend. Moderate leverage (~0.47 historically) suggests limited refinancing pressure and preserved flexibility for strategic investments over the next 2–6 months.

Negative Factors

Weakening Profitability

A material drop in net income and operating profit over the latest year signals margin compression and reduced earnings power. If margins remain pressured, the company will face constrained internal funding for growth, weaker returns on incremental capital, and a longer recovery path to prior profitability levels absent structural cost or pricing improvements.

Zim Laboratories Ltd. Business Overview & Revenue Model

Company Description

Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally,...

Read more

Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally,...

How the Company Makes Money

Zim Laboratories primarily makes money by selling pharmaceutical finished-dosage products. Key revenue streams include: (1) Branded/portfolio sales: revenue from marketing and selling its own formulations (including differentiated oral drug-delive...

Read more

Zim Laboratories primarily makes money by selling pharmaceutical finished-dosage products. Key revenue streams include: (1) Branded/portfolio sales: revenue from marketing and selling its own formulations (including differentiated oral drug-delive...

Zim Laboratories Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	3.66B	3.74B	3.74B	3.68B	3.99B	3.31B
Gross Profit	1.85B	1.25B	730.04M	1.86B	903.81M	1.67B
EBITDA	431.55M	300.10M	495.11M	454.76M	582.00M	452.62M
Net Income	65.86M	58.38M	121.65M	172.46M	244.34M	145.50M
Balance Sheet
Total Assets	4.70B	5.39B	4.72B	4.47B	3.42B	3.42B
Cash, Cash Equivalents and Short-Term Investments	50.12M	278.02M	20.37M	96.41M	64.66M	34.20M
Total Debt	1.23B	1.26B	1.18B	1.12B	620.00M	533.14M
Total Liabilities	2.19B	2.43B	2.20B	2.08B	1.41B	1.66B
Stockholders Equity	2.51B	2.96B	2.52B	2.39B	2.00B	1.76B
Cash Flow
Free Cash Flow	40.45M	-75.72M	3.57M	-576.45M	15.00M	339.81M
Operating Cash Flow	199.18M	368.15M	411.55M	162.78M	381.68M	492.06M
Investing Cash Flow	-155.70M	-565.23M	-399.27M	-730.13M	-362.04M	-145.71M
Financing Cash Flow	-34.19M	410.81M	-91.05M	595.34M	5.46M	-329.70M

Zim Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 71.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Positive. The current price of 71.11 is below the 20-day moving average (MA) of 107.04, below the 50-day MA of 96.28, and below the 200-day MA of 77.73, indicating a bullish trend. The MACD of 5.15 indicates Negative momentum. The RSI at 71.92 is Negative, neither overbought nor oversold. The STOCH value of 67.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZIMLAB.

Zim Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	62 Neutral	₹3.56B	27.09	―	―	36.73%	30.29%
KILITCH	61 Neutral	₹6.38B	20.74	―	―	18.74%	11.32%
ZIMLAB	60 Neutral	₹6.10B	96.06	―	―	-1.22%	-52.32%
BAFNAPH	56 Neutral	₹3.70B	32.96	―	―	3.26%	167.18%
ALBERTDAVD	55 Neutral	₹4.05B	-271.81	―	0.66%	-3.52%	-108.70%
VALIANTLAB	54 Neutral	₹3.75B	-115.29	―	―	78.04%	-16.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%